Pacer Advisors Inc. Has $8.92 Million Position in Harmony Biosciences Holdings, Inc. $HRMY

Pacer Advisors Inc. grew its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 9.7% during the 1st quarter, HoldingsChannel reports. The fund owned 318,527 shares of the company’s stock after acquiring an additional 28,174 shares during the period. Pacer Advisors Inc.’s holdings in Harmony Biosciences were worth $8,922,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Ruffer LLP acquired a new position in Harmony Biosciences in the 4th quarter worth about $1,536,000. CX Institutional raised its stake in shares of Harmony Biosciences by 19.7% during the 4th quarter. CX Institutional now owns 275,809 shares of the company’s stock worth $10,321,000 after purchasing an additional 45,376 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Harmony Biosciences during the 4th quarter worth about $655,000. Convergence Investment Partners LLC acquired a new stake in shares of Harmony Biosciences during the 4th quarter valued at about $961,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Harmony Biosciences by 32.9% during the 4th quarter. BNP Paribas Financial Markets now owns 525,145 shares of the company’s stock valued at $19,651,000 after buying an additional 130,001 shares during the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

Key Harmony Biosciences News

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: Quarterly results exceeded expectations: Harmony reported adjusted earnings of $1.28 per share, above the roughly $0.96–$0.97 consensus estimate, while revenue reached $261.3 million versus expectations of approximately $250.8 million. Revenue grew 30.3% year over year, supported by continued growth in its WAKIX narcolepsy treatment. Harmony Biosciences Q2 earnings report
• Positive Sentiment: WAKIX momentum and guidance support the outlook: WAKIX net revenue rose 30% to $261.3 million, and estimated average patients increased by 450 to 8,950. Management reiterated its 2026 WAKIX net-revenue forecast of $1.0 billion to $1.04 billion, reducing near-term uncertainty. Harmony Biosciences Q2 2026 revenue and pipeline update
• Positive Sentiment: Pipeline milestones add potential long-term value: Initial Phase 1 data for orexin-2 agonist BP-205 showed favorable pharmacokinetic, safety and tolerability profiles. Additional Phase 1 data are expected in the fourth quarter, with a Phase 1b study beginning in the third quarter and Phase 2 trials planned for mid-2027. The pitolisant GR NDA was accepted, with a target FDA decision date of April 1, 2027. BP-205 clinical data and pipeline update
• Positive Sentiment: Analysts raised valuation targets: Needham increased its price target from $45 to $50 and maintained a Buy rating. Another report cited a target increase to $51, reinforcing bullish sentiment after the earnings release. Needham price target increase Additional Harmony Biosciences price target increase

Harmony Biosciences Stock Performance

HRMY opened at $38.78 on Wednesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.56 and a current ratio of 3.58. The company has a market cap of $2.24 billion, a PE ratio of 15.64, a price-to-earnings-growth ratio of 0.33 and a beta of 0.96. The stock has a 50-day moving average of $34.76 and a 200-day moving average of $32.54. Harmony Biosciences Holdings, Inc. has a 52-week low of $25.52 and a 52-week high of $40.87.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $1.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.96 by $0.32. Harmony Biosciences had a return on equity of 17.19% and a net margin of 16.20%.The business had revenue of $261.28 million for the quarter, compared to the consensus estimate of $250.77 million. During the same period last year, the business earned $0.92 EPS. The firm’s revenue was up 30.3% compared to the same quarter last year. As a group, equities research analysts forecast that Harmony Biosciences Holdings, Inc. will post 3.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on HRMY. Weiss Ratings upgraded Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, June 23rd. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Harmony Biosciences from $30.00 to $36.00 and gave the company a “hold” rating in a research note on Tuesday, June 30th. Mizuho boosted their target price on shares of Harmony Biosciences from $50.00 to $51.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. HC Wainwright restated a “buy” rating and set a $55.00 price target on shares of Harmony Biosciences in a research note on Thursday, July 16th. Finally, Zacks Research upgraded shares of Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $44.38.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.